Pancreatic Cancer Research

Journal articleFuture Oncol2023

Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.

Journal
Future Oncol
Published
27 July 2023
Citations
4
License
cc by-nc-nd

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract cc by-nc-nd

Aim: The RAISE project aimed to find a surrogate end point to predict treatment response early in patients with enteropancreatic neuroendocrine tumors (NET). Response heterogeneity, defined as the coexistence of responding and non-responding lesions, has been proposed as a predictive marker for progression-free survival (PFS) in patients with NETs. … Excerpt only: this text is the publisher’s. Read it in full at the source.